Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases
|
By LabMedica International staff writers Posted on 20 Apr 2021 |

Illustration
Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade. Additionally, PCR advances, fulfillment of the human genome project, and expanding R&D will increase the utilization of biomarker profiling for sickness diagnostics, thus further driving market growth.
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services.
The interest in genomic examination strategies has increased consistently during the most recent decade due to their expanding use in the analysis of major illnesses (like HIV, tuberculosis, intestinal sickness, and hepatitis) and hereditary problems (like malignancy). The development in the commonness of target illnesses worldwide, combined with the demonstrated adequacy of qPCR and dPCR examination in the determination and assessment of sickness-causing microorganisms, will drive the utilization of clinical indicative tests (including qPCR and dPCR investigation) and support market development.
Geographically, North America is expected to dominate the global digital PCR and real-time PCR market, followed by Europe. The development of the North American qPCR and dPCR market will be driven by an expanded selection of innovative and novel genomic examination items (including progressed qPCR and dPCR items), accessibility to R&D financing for genomic research, growing utilization of PCR methods in clinical diagnostics and criminology, and early commercialization of qPCR/dPCR items.
Related Links:
TMR Research
Latest Industry News
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
- Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing
- Collaboration Explores Clinical Use of Single-Cell and Spatial Technologies
- Partnership Brings Automated Pathology Archiving Solutions to U.S. Labs
- New Collaboration Integrates Low-Code Automation into Laboratory Platform
- LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
- Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
- Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Seed Amplification Test Expands Access to Neurodegenerative Disease Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Channels
Clinical Chemistry
view channel
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read more
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read moreMolecular Diagnostics
view channel
Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more
Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
Recurrent hepatocellular carcinoma (HCC) after surgery remains a major cause of poor outcomes and contributes to liver cancer’s rank as the world’s third leading cause of cancer death. The burden is particularly... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channelProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more







